RETREATMENT OF CHRONIC HEPATITIS C INFECTION – REVIEW OF CURRENT RECOMMENDATIONS AND CLINICAL CASE
DOI:
https://doi.org/10.11603/1681-2727.2024.3.14880Keywords:
chronic hepatitis C, resistance, direct action antivirals, retreatment, treatment failureAbstract
The paper presents a clinical case of successful treatment of chronic hepatitis C (CHC) relapse in a patient with liver cirrhosis. RAS mutation testing was performed for this patient and its results were taken into account for retreatment decision. Although the failure rate after antiviral treatment of CHC is uncommon, but access to HCV treatment is increasing worldwide and, accordingly, the number of relapsed patients who will require retreatment will also increase. Modern regimens for re-treatment of CHC are available in Ukraine as for patients without cirrhosis as for patients with decompensated cirrhosis. Long lasting monitoring of patients with liver cirrhosis should be continued even after reaching SVR12 and SVR24. In case of increased activity of transaminases, they should be assigned an HCV PCR test to rule out/confirm relapse or re-infection with HCV.
References
Wei, L., Lim, S. G., Xie, Q., Văn, K. N., Piratvisuth, T., Huang, Y., ... & Jia, J. (2019). Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. The Lancet Gastroenterology & Hepatology, 4(2), 127-134. DOI:10.1016/S2468-1253(18)30343-1.
Hezode, C., Reau, N., Svarovskaia, E. S., Doehle, B. P., Shanmugam, R., Dvory-Sobol, H., ... & Zeuzem, S. (2018). Resistance analysis in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. Journal of hepatology, 68(5), 895-903. DOI: 10.1016/j.jhep.2017.11.032.
Pawlotsky, J. M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., ... & Wedemeyer, H. (2018). EASL recommendations on treatment of hepatitis C 2018. Journal of hepatology, 69(2), 461-511. DOI:10.1016/j.jhep.2018.03.026
Sarrazin, C. (2021). Treatment failure with DAA therapy: Importance of resistance. Journal of Hepatology, 74(6), 1472-1482. DOI:10.1016/j.jhep.2021.03.004.
Pawlotsky, J. M. (2016). Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology, 151(1), 70-86. DOI:10.1053/j.gastro.2016.04.003.
Sarrazin, C. (2016). The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. Journal of hepatology, 64(2), 486-504. DOI:10.1016/j.jhep.2015.09.011.
Boeke, C. E., Hiebert, L., Waked, I., Tsertsvadze, T., Sharvadze, L., Butsashvili, M., ... & Ramers, C. B. (2022). Retreatment of chronic hepatitis C infection: real-world regimens and outcomes from national treatment programs in three low-and middle-income countries. Clinical Infectious Diseases, 74(3), 513-516. DOI:10.1093/cid/ciab461.
Державний реєстр лікарських засобів України. URL: http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlist?opendocument (дата звернення: 12.07.2024).
Bourlière, M., Gordon, S. C., Flamm, S. L., Cooper, C. L., Ramji, A., Tong, M., ... & Zeuzem, S. (2017). Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. New England Journal of Medicine, 376(22), 2134-2146. DOI:10.1056/NEJMoa1613512.
Welzel, T. M., Bhardwaj, N., Hedskog, C., Chodavarapu, K., Camus, G., McNally, J., ... & Agarwal, K. (2017). Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. Journal of hepatology, 67(2), 224-236. DOI:10.1016/j.jhep.2017.03.014.
Bhattacharya, D., Aronsohn, A., & Price, J. (2023). Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America, ciad319-ciad319. DOI: 10.1093/cid/ciad319.
Pawlotsky, J. M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., ... & European Association for the Study of the Liver. (2020). EASL recommendations on treatment of hepatitis C: final update of the series. Journal of hepatology, 73(5), 1170-1218. DOI:10.1016/j.jhep.2020.08.018.
Wyles, D., Weiland, O., Yao, B., Weilert, F., Dufour, J. F., Gordon, S. C., ... & Poordad, F. (2019). Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. Journal of hepatology, 70(5), 1019-1023. DOI:10.1016/j.jhep.2019.01.031.
Pearlman, B., Perrys, M., & Hinds, A. (2019). Sofosbuvir/velpatasvir/voxilaprevir for previous treatment failures with glecaprevir/pibrentasvir in chronic hepatitis C infection. Official journal of the American College of Gastroenterology| ACG, 114(9), 1550-1552. DOI:10.14309/ajg.0000000000000248.
Bernhard, B., & Stickel, F. (2020). Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report. Zeitschrift für Gastroenterologie, 58(05), 451-455. DOI:10.1055/a-1131-8058.
Dietz, J., Di Maio, V. C., de Salazar, A., Merino, D., Vermehren, J., Paolucci, S., ... & Schmidt, W. (2021). Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. Journal of Hepatology, 74(4), 801-810. DOI:10.1016/j.jhep.2020.11.017.
Gane, E. J., Shiffman, M. L., Etzkorn, K., Morelli, G., Stedman, C. A., Davis, M. N., ... & GS-US-342-1553 Investigators. (2017). Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. Hepatology, 66(4), 1083-1089. DOI:10.1002/hep.29256.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Л. О. Кондратюк, О. В. Безродна
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal Infectious Disease (Infektsiini Khvoroby) allows the author(s) to hold the copyright without registration
Users can use, reuse and build upon the material published in the journal but only for non-commercial purposes
This journal is available through Creative Commons (CC) License BY-NC "Attribution-NonCommercial" 4.0
